文献速递认知障碍与痴呆

唐氏综合征与常染色体显性阿尔茨海默病脑脊液生物标志物比较

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
PubMed 文献 · Lancet Neurol · 2021-01-01

该横断面研究比较了唐氏综合征成人、常染色体显性阿尔茨海默病突变携带者及非携带同胞的脑脊液生物标志物,发现唐氏综合征的阿尔茨海默病相关脑脊液标志物模式与突变携带者高度相似,且痴呆者异常更显著。

要点

  • 唐氏综合征成人脑脊液Aβ42/Aβ40比值降低、磷酸化tau相关过程及神经元轴突突触损伤标志物升高,模式与常染色体显性阿尔茨海默病突变携带者相似。
  • 唐氏综合征患者Aβ和YKL-40浓度整体更高,无症状阶段tau和NfL可能升高。
  • 脑脊液生物标志物异常程度在痴呆患者中更明显。

核心结论

  • 唐氏综合征成人的阿尔茨海默病相关脑脊液生物标志物模式与常染色体显性阿尔茨海默病突变携带者高度相似,支持两者共享疾病机制。

研究设计与样本

  • 横断面研究,纳入ABC-DS研究中41名唐氏综合征成人、DIAN研究中192名常染色体显性阿尔茨海默病突变携带者及108名非携带同胞,年龄30-61岁,共341人。

临床怎么用

  • 脑脊液生物标志物可用于评估唐氏综合征成人阿尔茨海默病病理进展,尤其关注Aβ42/Aβ40比值、磷酸化tau及损伤标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease pathology by the age of 40 years and are at high risk for dementia given their increased life expectancy compared with adults with Down syndrome in the past. We aimed to compare CSF biomarker patterns in Down syndrome with those of carriers of autosomal dominant Alzheimer's disease mutations to enhance our understanding of disease mechanisms in these two genetic groups at high risk for Alzheimer's disease. METHODS: We did a cross-sectional study using data from adults enrolled in the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study, a multisite longitudinal study of Alzheimer's disease in Down syndrome, as well as a cohort of carriers of autosomal dominant Alzheimer's disease mutations and non-carrier sibling controls enrolled in the Dominantly Inherited Alzheimer Network (DIAN) study. For ABC-DS, participants with baseline CSF, available clinical diagnosis, and apolipoprotein E genotype as of Jan 31, 2019, were included in the analysis. DIAN participants with baseline CSF, available clinical diagnosis, and apolipoprotein E genotype as of June 30, 2018, were evaluated as comparator groups. CSF samples obtained from adults with Down syndrome, similarly aged carriers of autosomal dominant Alzheimer's disease mutations, and non-carrier siblings (aged 30-61 years) were analysed for markers of amyloid β (Aβ1-40, Aβ1-42); tau phosphorylated at threonine 181-related processes; neuronal, axonal, or synaptic injury (total tau, visinin-like protein 1, neurofilament light chain [NfL], synaptosomal-associated protein 25); and astrogliosis and neuroinflammation (chitinase-3-like protein 1 [YKL-40]) via immunoassay. Biomarker concentrations were compared as a function of dementia status (asymptomatic or symptomatic), and linear regression was used to evaluate and compare the relationship between biomarker concentrations and age among groups. FINDINGS: We assessed CSF samples from 341 individuals (178 [52%] women, 163 [48%] men, aged 30-61 years). Participants were adults with Down syndrome (n=41), similarly aged carriers of autosomal dominant Alzheimer's disease mutations (n=192), and non-carrier siblings (n=108). Individuals with Down syndrome had patterns of Alzheimer's disease-related CSF biomarkers remarkably similar to carriers of autosomal dominant Alzheimer's disease mutations, including reductions (all p<0·0080) in Aβ1-42 to Aβ1-40 ratio and increases in markers of phosphorylated tau-related processes; neuronal, axonal, and synaptic injury (p<0·080); and astrogliosis and neuroinflammation, with greater degrees of abnormality in individuals with dementia. Differences included overall higher concentrations of Aβ and YKL-40 (both p<0·0008) in Down syndrome and potential elevations in CSF tau (p<0·010) and NfL (p<0·0001) in the asymptomatic stage (ie, no dementia symptoms). FUNDING: National Institute on Aging, Eunice Kennedy Shriver National Institute of Child Health and Human Development, German Center for Neurodegenerative Diseases, and Japan Agency for Medical Research and Development.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Fagan AM, Henson RL, Li Y, et al. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2021. PMID: 34302786. doi:10.1016/S1474-4422(21)00139-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。